首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1477211

免疫疗法药物市场，依治疗类型、按给药途径、按适应症、按配销通路、按地理位置

Immunotherapy Drugs Market, By Therapy Type, By Route of Administration, By Indication, By Distribution Channel, By Geography

出版日期: 2024年04月11日 | 出版商:

Coherent Market Insights | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计2024年全球免疫疗法药物市场价值为1,665.5亿美元，预计到2031年将达到3,517.3亿美元，2024年至2031年年复合成长率（CAGR）为11.3%。

报告范围		报告详情
基准年：	2023年	2024 年市场规模：	1665.5 亿美元
历史数据：	2019年至2023年	预测期：	2024年至2031年
预测 2024 年至 2031 年复合年增长率：	11.30%	2031 年价值预测：	3517.3 亿美元

数字。全球免疫治疗药物市场占有率（%），按地区，2024年

免疫疗法药物利用人体的免疫系统来对抗癌症和其他疾病。这些药物透过增强现有的免疫细胞或将新的免疫细胞引入体内来刺激免疫系统。免疫疗法的主要类型包括单株抗体、癌症疫苗、检查点抑制剂和过继性细胞转移疗法。免疫疗法药物正日益成为各种癌症类型的治疗标准，因为与化疗相比，这些药物已被证明可以提供持久的缓解率和更轻微的副作用。过去几年，在新药核准和不同疾病适应症的采用不断增加的推动下，市场出现了显着增长。

市场动态：

全球免疫疗法药物市场的成长是由全球癌症和其他慢性病盛行率上升所推动的。由于开发新型免疫疗法的研发资金增加、FDA 对免疫疗法的一致批准以及相对于其他可用治疗方案的优越性等因素，该市场获得了动力。然而，这些药物的高成本以及某些地区的报销问题是该市场的主要限制因素。市场参与者也正在投资管道产品，以将当前的治疗领域扩展到新的适应症。

研究的主要特点：

该报告对全球免疫疗法药物市场进行了深入分析，并提供了以2023年为基准年的预测期（2024-2031）的市场规模（十亿美元）和年复合成长率（CAGR%）。
它阐明了不同细分市场的潜在收入机会，并解释了该市场有吸引力的投资主张矩阵。
这项研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采取的竞争策略的重要见解。
它根据以下参数描述了全球免疫疗法药物市场的主要参与者——公司亮点、产品组合、主要亮点、财务表现和策略。
该报告的见解将使行销人员和公司管理当局能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
全球免疫疗法药物市场报告迎合了该行业的各个利益相关者，包括投资者、供应商、产品製造商、分销商、新进业者和财务分析师。
利害关係人可以透过用于分析全球免疫疗法药物市场的各种策略矩阵轻鬆做出决策。

概述
免疫检查点抑制剂
单株抗体
裸单株抗体
缀合单株抗体
双特异性单株抗体
疫苗
预防疫苗
治疗性疫苗
过继性细胞疗法
肿瘤浸润淋巴细胞（TIL）疗法
CAR T细胞疗法
工程 T 细胞受体 (TCR) 疗法
自然杀手（NK）细胞疗法
免疫系统调节剂
干扰素
免疫调节剂 (IMiD)
白血球介素
溶瘤病毒治疗

第 6 章：全球免疫疗法药物市场，依给药途径划分，2019 - 2031 年（十亿美元）

概述
静脉注射 (IV)
口服
肌肉注射
皮下
其他的

第 7 章：全球免疫疗法药物市场，按适应症划分，2019 - 2031 年（十亿美元）

概述
癌症
肺癌
淋巴瘤
乳癌
皮肤癌
膀胱癌
大肠直肠癌
肾癌
其他的
自体免疫疾病
其他的

第 8 章：全球免疫疗法药物市场，按配销通路，2019 - 2031 年（十亿美元）

概述
医院药房
零售药局
网路药局

第 9 章：2019 - 2031 年全球免疫疗法药物市场（按地区）（十亿美元）

介绍
北美洲
我们
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
拉丁美洲其他地区
欧洲
英国
德国
义大利
法国
西班牙
俄罗斯
欧洲其他地区
亚太地区
中国
印度
日本
东协
澳洲
韩国
亚太地区其他地区
中东
海湾合作委员会
以色列
中东其他地区
非洲
北非
中非
南非

第 10 章：竞争格局

公司简介
- Bristol-Myers Squibb Company
- Pfizer Inc
- Novartis AG
- Merck & Co., Inc.
- AstraZeneca
- Amgen Inc.
- GSK plc.
- Gilead Sciences, Inc.
- Johnson & Johnson
- Actym Therapeutics, Inc.
- Fate Therapeutics
- Gritstone bio
- Incyte
- Acumen Pharmaceuticals, Inc
- Arcus Biosciences, Inc.
- immunitybio inc
- Autolus Therapeutics
- ADC Therapeutics SA.
- BioNTech SE
- Cellectis

第 11 章：分析师建议

命运之轮
分析师观点
连贯的机会图

第 12 章：参考文献与研究方法

参考
研究方法论

简介目录

Product Code: CMI525

Global immunotherapy drugs market is estimated to be valued at USD 166.55 Bn in 2024 and is expected to reach USD 351.73 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 11.3% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 166.55 Bn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	11.30%	2031 Value Projection:	US$ 351.73 Bn

Figure . Global immunotherapy drugs market Share (%), By Region, 2024

Immunotherapy drugs utilize the body's immune system to fight cancer and other diseases. These drugs stimulate the immune system by either boosting existing immune cells or introducing new immune cells into the body. The major types of immunotherapies include monoclonal antibodies, cancer vaccines, checkpoint inhibitors, and adoptive cell transfer therapies. Immunotherapy drugs are increasingly becoming the standard of care for various cancer types as these have been shown to provide long-lasting response rates with milder side effects compared to chemotherapy. The market has witnessed significant growth over the past few years driven by new drug approvals and increasing adoption across different disease indications.

Market Dynamics:

Global immunotherapy drugs market growth is driven by rising prevalence of cancer and other chronic diseases worldwide. The market has gained momentum due to factors such as an increase in R&D funding for developing novel immunotherapies, consistent FDA approvals of immunotherapies, and superiority over other available treatment options. However, high costs associated with these drugs along with reimbursement issues in some regions act as key restraints for this market. The market players are also investing in pipeline products for expanding the current treatment landscape to new indications.

Key Features of the Study:

This report provides in-depth analysis of the global immunotherapy drugs market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global immunotherapy drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study includes Bristol-Myers Squibb Company, Pfizer Inc, Novartis AG, Merck & Co., Inc., AstraZeneca, Amgen Inc., GSK plc., Gilead Sciences, Inc., Johnson & Johnson, Actym Therapeutics, Inc., Fate Therapeutics., Gritstone bio, Incyte, Acumen Pharmaceuticals, Inc, Arcus Biosciences, Inc., immunitybio inc, Autolus Therapeutics, ADC Therapeutics SA., BioNTech SE, and Cellectis.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global immunotherapy drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immunotherapy drugs market.

Detailed Segmentation-

Therapy Type:
- Immune checkpoint inhibitors
- Monoclonal antibodies
- Naked monoclonal antibodies
- Conjugated monoclonal antibodies
- Bispecific monoclonal antibodies
- Vaccines
- Preventive Vaccines
- Therapeutic Vaccines
- Adoptive Cell Therapies
- Tumor-infiltrating lymphocyte (TIL) therapy
- CAR T-cell therapy
- Engineered T-cell receptor (TCR) therapy
- Natural killer (NK) cell therapy
- Immune System Modulators
- Interferons
- Immunomodulators (IMiDs)
- Interleukins
- Oncolytic Virus Therapy
Route of Administration:
- Intravenous (IV)
- Oral
- Intramuscular
- Subcutaneous
- Others
Indication:
- Cancer
- Lung Cancer
- Lymphoma
- Breast Cancer
- Skin Cancer
- Bladder Cancer
- Colorectal Cancer
- Kidney Cancer
- Others
- Autoimmune Diseases
- Others
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Bristol-Myers Squibb Company
- Pfizer Inc
- Novartis AG
- Merck & Co., Inc.
- AstraZeneca
- Amgen Inc.
- GSK plc.
- Gilead Sciences, Inc.
- Johnson & Johnson
- Actym Therapeutics, Inc.
- Fate Therapeutics.
- Gritstone bio
- Incyte
- Acumen Pharmaceuticals, Inc
- Arcus Biosciences, Inc.
- immunitybio inc
- Autolus Therapeutics
- ADC Therapeutics SA.
- BioNTech SE
- Cellectis

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Therapy Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Indication
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Recent Developments
Acquisitions and Partnerships Scenario
Technology Overview
Regulatory Scenario
Pricing Analysis
PEST Analysis

4. Global Immunotherapy Drugs Market- Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the market

5. Global Immunotherapy Drugs Market, By Therapy Type, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Immune checkpoint inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Monoclonal antibodies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Naked monoclonal antibodies
Conjugated monoclonal antibodies
Bispecific monoclonal antibodies
Vaccines
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Preventive Vaccines
Therapeutic Vaccines
Adoptive Cell Therapies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Tumor-infiltrating lymphocyte (TIL) therapy
CAR T-cell therapy
Engineered T-cell receptor (TCR) therapy
Natural killer (NK) cell therapy
Immune System Modulators
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Interferons
Immunomodulators (IMiDs)
Interleukins
Oncolytic Virus Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Immunotherapy Drugs Market, By Route of Administration, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Intravenous (IV)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Intramuscular
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Subcutaneous
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Immunotherapy Drugs Market, By Indication, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Lung Cancer
Lymphoma
Breast Cancer
Skin Cancer
Bladder Cancer
Colorectal Cancer
Kidney Cancer
Others
Autoimmune Diseases
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Immunotherapy Drugs Market, By Distribution Channel, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global Immunotherapy Drugs Market, By Region, 2019 - 2031, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Regions, 2019-2031
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
North Africa
Central Africa
South Africa

10. Competitive Landscape

Company Profiles
- Bristol-Myers Squibb Company
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- Pfizer Inc
- Novartis AG
- Merck & Co., Inc.
- AstraZeneca
- Amgen Inc.
- GSK plc.
- Gilead Sciences, Inc.
- Johnson & Johnson
- Actym Therapeutics, Inc.
- Fate Therapeutics
- Gritstone bio
- Incyte
- Acumen Pharmaceuticals, Inc
- Arcus Biosciences, Inc.
- immunitybio inc
- Autolus Therapeutics
- ADC Therapeutics SA.
- BioNTech SE
- Cellectis